Aptevo Therapeutics (APVO) Reports Q1, Provides an Update on Mipletamig
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
May 15, 2025 8:06 AM EDT9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials
Mipletamig triplet combination continues to outperform standard doublet benchmark
No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML
Cohort 2 enrollment is complete, and Cohort 3 is now enrolling
Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter... More
